CME Objectives\Questions
CME Objectives
Upon completion of this educational activity, participants should be able to:
- discuss current scientific data regarding the diagnosis and treatment of neurological disease;
- discuss the pathogenesis and treatment of pain;
- describe the basic science of brain function;
- discuss new information regarding new drugs for commonly diagnosed neurological conditions and new uses for traditional drugs;
- identify nonclinical issues of importance for the neurologist.
CME Questions
1. Spreading cortical depolarizations following acute brain injury may be responsible for secondary ischemic damage.
a. True
b. False
2. Which of the following is NOT a diagnostic criteria for NMOSD?
a. Optic neuritis and transverse myelitis are present.
b. Isolated optic neuritis may occur.
c. Positive antibodies for NMO IgG.
d. Brain MRI not diagnostic for multiple sclerosis.
3. Which of the following statements is false about optic neuritis?
a. Optic neuritis usually recovers spontaneously.
b. Intravenous corticosteroids speeds recovery of optic neuritis.
c. Optic neuritis may be an isolated event, or part of multiple sclerosis.
d. Neuromyelitis optica never presents with isolated optic neuritis.
e. Neuromyelitis optica may respond to plasma exchange.
4. Interlaminar and transforaminal epidural steroid injection are equally efficacious for unilateral radicular pain.
a. True
b. False
5. Which of the following statements is true?
a. Intravenous DHE used for 5 days was found to be superior to intravenous valproate for treatment of refractory migraine.
b. Intravenous DHE decreases headache duration and severity in new persistent daily headache.
c. Chest pain is the most common side effect noted with intravenous DHE.
d. At least half of patients with refractory cluster headache reported benefit from intravenous DHE.
6. Excessive daytime sleepiness may be a modifiable stroke risk factor.
a. True
b. False
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.